Tempus is a technology company that will collect, sort and analyze the clinical data from different organizations across the country and abroad to help in the research and treatment of cancer. The data gathered will be made available to different doctors, researchers and physicians to allow them to make better treatment plans for their patients. They have partnered with a number of different organizations and universities for the purpose of collection of their data and then analyzing them.
In a recent interview, the founder of the company, Eric Lefkofsky said that it was important to mix technology and medical science to be able to provide the researchers and the doctors with the right information that they need at the right time. Tempus is yet another effort to ensure that people with cancer that has increased odds can see a ray of hope and get treatment using real data and not just speculation. It is the aim of the company to provide as much information as they can to allow doctors to make better treatment plans. Eric Lefkofsky on Twitter.
Eric Lefkofsky, the CEO and the founder of Tempus is not new to the technology industry. He has founded a few technology companies like Echo Global Logistics, InnerWorkings, MediaOcean and more. Among these, the top is Groupon that now has a presence in many different countries across the globe. He is also associated with many different non-profit organizations. In fact, he and his wife, Liz created a family foundation under the name of Lefkofsky Family Foundation that has made a huge difference to many different communities. Apart from that, he is also a trustee of the Art Institute of Chicago for many years now. He is also the member of Steppenwolf Theatre Company.
Eric Lefkofsky is driven by passion when it comes to overlooking the working of his new company, Tempus. After his wife had been diagnosed with cancer, he realized how little information was there to help researchers and doctors to make important decisions. He wanted to create something that will allow cancer patients across the world to find all the information they need from one place.
Clay Siegall, Ph.D. is one of the founders of Seattle Genetics. The company was founded in 1998 and Dr. Siegall is the CEO. He is a scientist who focuses on cancer therapies. He has guided the company into the position of being the leader in the development of antibody-drug conjugates and secured the approval of the FDA for their product called Adcetris.
Seattle Genetics has collaborated with Takeda Pharmaceutical and become a global brand. They have received approval in over 65 countries. Dr. Siegall has additionally led the capital raising for Seattle Genetics and secured over $1.2 billion in private and public financing. Dr. Siegall worked for Bristol-Myers Squibb Pharmaceutical Research before he helped found Seattle Genetics. He also worked for the National Institutes of Health and the National Cancer Institute.
Dr. Siegall has received numerous awards including the 2012 Pacific Northwest Ernst & Young Entrepreneur of the Year and the 2013 University of Maryland Alumnus of the Year. He has written over seventy publications and has fifteen patents. Dr. Siegall additionally has a Ph.D. in Genetics and a B.S. in Zoology.
As the CEO of Seattle Genetics Dr. Siegall studies therapies for cancer. His antibody-based therapies have resulted in a diverse pipeline including the development of Adcetris also known as brentuximab vedotin. The therapy was approved by the FDA in 2011.
Dr. Clay Siegall has also been incredibly successful in raising capital for Seattle Genetics. He admits that when he was in his twenties he thought he had all the answers. Now he understands you simply learn what you can in life. He believes that interactions with intelligent people bring expertise into his life. His strategy in business is the collaboration with the leaders of industry in the field of oncology drug development. His collaborations have extended his technological reach and given him the ability to find new resources and approaches. Dr. Siegall does everything he can to help cancer patients as much as possible.
The development of biotechnology and research institutes across the world has made it easier to access information about different diseases. These institutes have been supporting experts who want to find solutions to diseases that have remained a mystery for many years. In recent years, many companies in the field of biotechnology embraced research and are looking for solutions to offer easy ways of treating cancer. The success that has been witnessed so far has allowed for the development of technologies that allow patients to receive better care and specialized treatment that offers a bigger margin of success.
Seattle Genetics, one of the biotechnology companies that have invested largely in cancer research, has succeeded in the development of different drug pipelines and technologies that have been useful in treating cancer. One of their most notable drug pipelines is ADCETRIS, which has been earning the company the biggest revenue amount. ADCETRIS has proved successful and is currently adopted by over 60 countries in different parts of the world.
Another milestone that defined the dedication of Seattle Genetics to finding solutions for cancer treatment is the ADC Technology. Antibody Drug Conjugates work seamlessly in the treatment of cancer by targeting and killing harmful cells while at the same time ignoring healthy cells. This is a better technology than the radiation of waves, which kill all cells in the region targeted.
About Clay Siegall
Clay Siegall, the President, Board Chairman and CEO of Seattle Genetics, is a highly skilled clinical scientist, whose career has been confined to looking for solutions to effectively defeat cancer. He founded the company in 1998 and since then he has been supporting research and the design of products that are aimed at supporting the fight to cure cancer.
Prior to building Seattle Genetics, Clay Siegall worked at the Bristol-Meyers Squibb Research Institute (1991 to 1997). He also prior to this worked at several companies and corporations including the National Cancer Institute as well as the National Institute of Health (1988 to 1991). Clay Siegall attended the University of Maryland to study Zoology and he later joined Washington University and graduated with a PhD in Genetics.
Mirna Therapeutics recently announced the appointment of Dr. Clay B Siegall as one of the outside directors of its board of directors. Mirna Therapeutics is a very famous biotechnology firm that was founded to develop and commercialize microRNA therapeutics.
Clay B. Siegall is one of the co-founder of Seattle Genetics. He is also the president and Chief Executive Officer of the company that was started several years ago. He also chairs the board of directors for Seattle Genetics. Mr. Siegall is a PhD holder, with a lot of experience in the biotechnology industry.
Mirna Therapeutics management is very excited about the new appointment. Dr. Siegall is expected to bring a lot of changes in the company since he has a lot of expertise in pharmaceutical world. He also boasts of his success in building a very successful oncology company. Mirna Therapeutics team with benefit from Dr. Siegall contributions, especially when developing microRNA therapeutics
MicroRNA therapeutics is actually a very exciting area of cancer research. According to Dr. Siegall, Mirna is one of the companies that is perfectly positioned with the right products. He was very excited to join the company to as part of the Board of Directors.
Dr. Siegall co-founded a company known as Seattle Genetics in the year 1998. The company has done quite well under his leadership, and it has managed to build a wide range of antibody therapies that can address different medical needs of people suffering from cancer. The first commercial product from Seattle Genetics was known as ADCETRIS, and it was approved in the market in 2011.
Seattle Genetics is also believed to have entered into different strategic collaborations with some of the leading biotechnology and some pharmaceutical companies in the oncology department. All this while, Dr. Siegall has been in charge of raising the capital for the company. So far, he has managed to secure more than six hundred million dollars through private and public financings.